Moreover, early-phase clinical studies have demonstrated promising antitumor activity and restoration of antitumor immunity with combinations of MEK inhibitors and anti-PD-L1 antibodies in patients with BRAFV600 wild-type advanced melanoma (13). This evidence concerns the gene CD274 and melanoma.